SCORAD Severity Band Threshold

Analysis From Dupilumab Clinical Trials in Adults

With Moderate-to-Severe Atopic Dermatitis

Andreas Wollenberg1,2,3, Eric L. Simpson4, Yael A. Leshem5, Alain Taieb7, Norito Katoh8, Jingdong Chao9, Ana B. Rossi10, Amy Praestgaard10

1University Hospital Augsburg, Augsburg, Germany; 2Ludwig Maximilian University of Munich, Munich, Germany; 3Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany; 4Oregon Health and Science University, Portland, OR, USA; 5Rabin Medical Center, Petach Tikva, Israel; 6School of Medicine, Tel-Aviv University, Tel Aviv, Israel; 7INSERM U1312 BRIC, University of Bordeaux, Bordeaux, France; 8Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan; 9Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; 10Sanofi, Cambridge, MA, USA

Introduction

- Multiple severity threshold bands have been published to translate the numeric scoring of the SCORAD index into clinically meaningful categories.
- Further analyses using larger patient numbers from other clinical settings may provide additional insights into AD severity and outcomes

Methods

- Pooled total SCORAD data from all patients receiving dupilumab and placebo (all visits, excluding first visit) were collected from 5 double-blind, randomized, placebo-controlled trials of dupilumab in adults with moderate-to-severe AD (NCT01859988, NCT02277743, NCT02277769, NCT02165986, NCT02755649).
- SCORAD values (range 0–103) were anchored to the IGA, and Spearman’s rank correlations were calculated.
- Potential threshold values were calculated by means (with spline regression), medians, and modes, and results of previous analyses (modified to include 5 severity categories).
- Thresholds for BSA (0–100) and total SCORAD subscales (oSCORAD [0–83], Pruritus VAS [0–10], and Sleep Loss VAS [0–10]) were also evaluated.
- Goodness-of-fit and concordance between bands and anchors were assessed using R² and quadratic weighted kappa (κ)-coefficients.

Results

- Conclusions:
  - The SCORAD threshold bands developed in this anchor-based analysis utilize a large, global, diverse data set of adult patients with AD from clinical trials and used spline regressions as a novel methodology.
  - These potential severity bands may enhance the understanding of AD severity and disease stratification.

Objective

To report an analysis of SCORAD severity bands using a large, pooled dataset of global, randomized, placebo-controlled clinical trials of dupilumab in adults with moderate-to-severe AD

Figure. Potential severity thresholds for total SCORAD (A) and BSA and SCORAD subscales by medians (B).